

Inflammatory Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/I9C44C2F2A84EN.html>

Date: May 2024

Pages: 133

Price: US\$ 6,499.00 (Single User License)

ID: I9C44C2F2A84EN

Abstracts

The 7 major inflammatory pain markets reached a value of US\$ 68.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 89.3 Billion by 2034, exhibiting a growth rate (CAGR) of 2.46% during 2024-2034.

The inflammatory pain market has been comprehensively analyzed in IMARC's new report titled "Inflammatory Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Inflammatory pain refers to increased sensitivity that results from the natural response of the immune system to injury or infection. This condition can lead to the release of various chemical substances, such as prostaglandins, cytokines, histamines, etc., which sensitize the pain receptors and contribute to the perception of pain. It is often characterized by swelling, redness, heat, and pain in the affected area. The ailment can be categorized as acute or chronic. Acute inflammatory pain occurs suddenly and lasts for a short duration, whereas chronic inflammatory pain persists for weeks, months, or even years. The diagnosis of this illness involves a combination of medical history evaluation, physical examination, and diagnostic tests. Numerous blood workups, such as erythrocyte sedimentation rate, C-reactive protein, anti-cyclic citrullinated peptide antibody, etc., are recommended to assess the specific autoimmune or inflammation responsible for the disease. The healthcare provider may also perform various imaging techniques, like X-rays and ultrasound, to provide detailed images of the affected area that help in identifying signs of inflammation, damage, or structural abnormalities.

The increasing cases of tissue injuries due to cuts, burns, fractures, etc., which release certain chemical signals that trigger cytokine responses, are primarily driving the inflammatory pain market. In addition to this, the rising incidences of autoimmune

disorders, leading to the accumulation of antigen-antibody complexes in joints, blood vessels, or various other organs, are also creating a positive outlook for the market. Moreover, the widespread adoption of non-steroidal anti-inflammatory drugs (NSAIDs), like ibuprofen, naproxen, aspirin, etc., that help to relieve pain and reduce discomfort associated with the ailment is further bolstering the market growth. Apart from this, the inflating application of physical therapy, owing to its several advantages, such as enhanced overall functional capacity, improved joint mobility, and promoted tissue healing, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of transcutaneous electrical nerve stimulation techniques, which deliver low-voltage electrical currents through electrodes placed on the skin and help to reduce pain signals as well as provide symptom relief, is expected to drive the inflammatory pain market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the inflammatory pain market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for inflammatory pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the inflammatory pain market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the inflammatory pain market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the inflammatory pain market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current inflammatory pain marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the inflammatory pain market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the inflammatory pain market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the inflammatory pain market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of inflammatory pain across the seven major markets?

What is the number of prevalent cases (2018-2034) of inflammatory pain by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of inflammatory pain by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with inflammatory pain across the seven major markets?

What is the size of the inflammatory pain patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of inflammatory pain?

What will be the growth rate of patients across the seven major markets?

Inflammatory Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for inflammatory pain drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the inflammatory pain market?

What are the key regulatory events related to the inflammatory pain market?

What is the structure of clinical trial landscape by status related to the inflammatory pain market?

What is the structure of clinical trial landscape by phase related to the inflammatory pain market?

What is the structure of clinical trial landscape by route of administration related to the inflammatory pain market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 INFLAMMATORY PAIN - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 INFLAMMATORY PAIN - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 INFLAMMATORY PAIN - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 INFLAMMATORY PAIN - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 INFLAMMATORY PAIN - UNMET NEEDS

10 INFLAMMATORY PAIN - KEY ENDPOINTS OF TREATMENT

11 INFLAMMATORY PAIN - MARKETED PRODUCTS

- 11.1 List of Inflammatory Pain Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 INFLAMMATORY PAIN - PIPELINE DRUGS

12.1 List of Inflammatory Pain Pipeline Drugs Across the Top 7 Markets

12.1.1 GSK3858279 - GlaxoSmithKline

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 AFA281 - AfaSci

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. INFLAMMATORY PAIN - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. INFLAMMATORY PAIN – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 INFLAMMATORY PAIN - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Inflammatory Pain - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Inflammatory Pain - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

- 15.3.1 Inflammatory Pain - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Inflammatory Pain - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Inflammatory Pain - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Inflammatory Pain - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Inflammatory Pain - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Inflammatory Pain - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Inflammatory Pain - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Inflammatory Pain - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Inflammatory Pain - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Inflammatory Pain - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Inflammatory Pain - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Inflammatory Pain - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Inflammatory Pain - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Inflammatory Pain - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Inflammatory Pain - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 Inflammatory Pain - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Inflammatory Pain - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

15.8.3 Inflammatory Pain - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 Inflammatory Pain - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 Inflammatory Pain - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Inflammatory Pain - Access and Reimbursement Overview

16 INFLAMMATORY PAIN - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 INFLAMMATORY PAIN MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 INFLAMMATORY PAIN MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Inflammatory Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/I9C44C2F2A84EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I9C44C2F2A84EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

